Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant Acinetobacter baumannii Using Checkerboard Information.

Menegucci TC, Fedrigo NH, Lodi FG, Albiero J, Nishiyama SAB, Mazucheli J, Carrara-Marroni FE, Voelkner NMF, Gong H, Sy SKB, Tognim MCB.

Microb Drug Resist. 2019 Nov;25(9):1266-1274. doi: 10.1089/mdr.2018.0283. Epub 2019 Jun 19.

PMID:
31216222
2.

Can the resistance profile affect the survival of Acinetobacter baumannii on hospital surfaces?

Lodi FG, Viana GF, Uber AP, Fedrigo NH, Montemezzo de Farias AP, Dos Anjos Szczerepa MM, Cardoso CL, Nishiyama SAB, Tognim MCB.

J Hosp Infect. 2019 Sep;103(1):e120-e122. doi: 10.1016/j.jhin.2019.03.005. Epub 2019 Mar 16. No abstract available.

PMID:
30885814
3.

Synergistic activity of polymyxin B combined with vancomycin against carbapenem-resistant and polymyxin-resistant Acinetobacter baumannii: first in vitro study.

Shinohara DR, Menegucci TC, Fedrigo NH, Migliorini LB, Carrara-Marroni FE, Maria Dos Anjos M, Cardoso CL, Nishiyama SAB, Tognim MCB.

J Med Microbiol. 2019 Mar;68(3):309-315. doi: 10.1099/jmm.0.000920. Epub 2019 Jan 21.

PMID:
30663954
4.

Pharmacodynamic Evaluation of Fosfomycin against Escherichia coli and Klebsiella spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities.

Fedrigo NH, Mazucheli J, Albiero J, Shinohara DR, Lodi FG, Machado ACDS, Sy SKB, Tognim MCB.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e02498-16. doi: 10.1128/AAC.02498-16. Print 2017 Aug.

Supplemental Content

Loading ...
Support Center